Synovial Sarcoma Clinical Trials 2024

What are the top hospitals conducting synovial sarcoma research?

In the battle against synovial sarcoma, a rare and challenging form of cancer, several top hospitals across the United States are leading the charge. One such institution is Massachusetts General Hospital in Boston, which currently has five active clinical trials dedicated to synovial sarcoma. With a total of seven synovial sarcoma trials conducted since their first recorded trial in 2006, this hospital stands at the forefront of research and treatment for this complex condition.

Joining them in this crucial endeavor is MD Anderson Cancer Center located in Houston. They too have five ongoing synovial sarcoma trials and share an equal number of all-time studies with Massachusetts General Hospital - seven completed investigations. However, their journey into exploring treatments for synovial sarcoma began more recently with their first recorded trial taking place in 2015.

Meanwhile, Memorial Sloan Kettering Cancer Center located in New york City is actively engaged in four clinical trials focused on advancing knowledge about synovial sarcoma. Since initiating its first recorded trial for this disease in 2014, they have contributed significantly to understanding and combating it through their cumulative seven all-time studies.

Further expanding our list of notable institutions is City of Hope situated in Duarte, California. With three ongoing clinical trials targeting synovial sarcoma since recording its inaugural investigation just two years ago (in 2019), City of Hope demonstrates dedication towards accelerating progress against this rare cancer variant.

Last but not least, Washington University School of Medicine based out of Saint Louis holds an admirable record with three active clinical trials centered around synovial sarcoma while boasting twelve past studies overall since commencing its pioneering exploration on this condition back in 2007.

These esteemed medical centers are instrumental forces driving advancements within the field by pushing boundaries through innovative research initiatives that aim to enhance our understanding and treatment options for those affected by synovial sarcoma

Which are the best cities for synovial sarcoma clinical trials?

New york, Los Angeles, and Boston emerge as the top cities for synovial sarcoma clinical trials. With 13 active trials each, these cities are at the forefront of research and development in this field. New York's ongoing studies focus on Tazemetostat, CFT8634, CAB-AXL-ADC among others. Los Angeles explores Doxorubicin, CAB-AXL-ADC, AL3818 alongside other potential treatments. Meanwhile, Boston investigates FHD-609, afamitresgene autoleucel (previously ADP-A2M4), CAB-AXL-ADC among various options. These cities offer individuals battling synovial sarcoma access to cutting-edge clinical trials that hold promise for improved treatment outcomes.

Which are the top treatments for synovial sarcoma being explored in clinical trials?

Synovial sarcoma, a rare and aggressive form of cancer, is the focus of intensive research in clinical trials. Notable treatments under exploration include:

• Tazemetostat: Engaging in two active trials and participating in four synovial sarcoma trials to date since its introduction in 2015.
• Letetresgene autoleucel: Currently involved in one ongoing trial dedicated to synovial sarcoma and has been listed as a treatment option since 2019.
• CFT8634: Partaking in one active clinical trial for synovial sarcoma after being first listed as a potential treatment choice just recently, in 2022.
• FHD-609: Actively tested within one trial for synovial sarcoma and initially introduced as an avenue of investigation in 2021.
• Second generation 4-1BBζ B7H3-EGFRt-DHFR: Participating exclusively within one current clinical trial dedicated specifically to examining its efficacy against synovial sarcoma. This innovative approach was first listed as a potential therapeutic option from the year 2020 onwards. Through these endeavors, researchers aim to uncover new breakthroughs that may bring hope to individuals battling this challenging disease.

What are the most recent clinical trials for synovial sarcoma?

Recent clinical trials offer new hope for patients with synovial sarcoma, a rare soft tissue cancer. Among these trials is a dose escalation phase study that aims to determine the optimal dosage for treating synovial sarcoma. Another trial focuses on the potential of CFT8634 in both Phase 1 and Phase 2, evaluating its effectiveness as a treatment option. In addition, there is an ongoing investigation into the efficacy of Pembrolizumab Injectable Product for this challenging cancer type. FHD-609 is also being studied in Phase 1 to explore its therapeutic benefits against synovial sarcoma. Lastly, researchers are examining definitive surgical resection as a treatment modality in early-stage cases of synovial sarcoma. With these promising advancements, we inch closer towards improved outcomes and better quality of life for individuals battling synovial sarcoma.

What synovial sarcoma clinical trials were recently completed?

Recent clinical trials have made significant strides in advancing the understanding and treatment of synovial sarcoma. Notably, Epizyme, Inc. successfully completed a trial investigating the efficacy of Tazemetostat in April 2020. Additionally, M.D. Anderson Cancer Center concluded their study on Autologous NY-ESO-1-specific CD8-positive T Lymphocytes in September 2018, while OHSU Knight Cancer Institute wrapped up a pharmacological study in March 2017. Furthermore, Dexrazoxane was investigated by Washington University School of Medicine and completed its trial in February 2016. These innovative trials represent crucial efforts to battle synovial sarcoma and provide hope for improved treatments for patients affected by this challenging disease.